Market Overview

UPDATE: Deutsche Bank Raines PT to $45 on Medtronic Following Top-Line Beat

Related MDT
Medtronic Completes Acquisition of Twelve, Inc.
Medtronic Initiates Global Study of Minimally Invasive Technology to Aid Lung Cancer Diagnosis

Deutsche Bank reiterated its Hold rating on Medtronic (NYSE: MDT) but increased its price target from $43 to $45.

Deutsche Bank noted, "Top line beats, but EPS in line; Maintain Hold. In F2Q13, Medtronic's sales grew 5% ex-FX driven by the successful launch and share gains in the drug-eluting stent business (which accounted for 1.6%-pts of growth). While sales were better, EPS was in-line with Consensus ($0.01 below our estimate) due mainly to lower gross margins. Medtronic managed the P&L noting it took one-time gains from selling treasuries and minority investments to help offset FX hedging losses. We maintain our Hold rating but we are slightly increasing our PT to $45 from $43 given the more stable top line performance in the quarter and expectations going forward."

Medtronic closed at $42.75 on Wednesday.

Latest Ratings for MDT

Sep 2015JefferiesMaintainsHold
Sep 2015Cowen & CompanyMaintainsOutperform
Aug 2015Credit SuisseAssumesOutperform

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Pre-Market Outlook Analyst Ratings


Related Articles (MDT)

View Comments and Join the Discussion!

Get Benzinga's Newsletters